Nanobiotix S.A. – Special Call
Company Participants
Joanne Choi
Laurent Levy – Co-Founder, President of the Executive Board & CEO
Conference Call Participants
Ruoxi Liao – Guggenheim Securities, LLC, Research Division
Clemence Thiers – Stifel, Nicolaus & Company, Incorporated, Research Division
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division
Lucy-Emma Codrington-Bartlett – Jefferies LLC, Research Division
Chiara Montironi
Xiaochuan Dai – UBS Investment Bank, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Nanobiotix New Results in patients with Refractory Melanoma conference call. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your speaker today, Joanne Choi. Head of U.S. Investor Relations. Please go ahead.
Joanne Choi
Thank you, Heidi. Good afternoon, and good morning. Thank you for joining Nanobiotix conference call to discuss new data from the third cohort of our Phase I 1100 study in melanoma presented at the Immunorad conference yesterday in Paris.
Joining me on the call today is Laurent Levy, our Co-Founder and Chief Executive Officer. Today’s call is being webcast and will be available on our website for replay. Before we begin, I would like to remind you that this call will include forward-looking statements within the meaning of securities laws. These forward-looking statements are based on current information, assumptions and expectations and are subject to significant risks and uncertainties that could cause the company’s actual results, including progress and timing of planned research and clinical development to differ materially from our current expectations.
We encourage you to review the full description of risk factors that can be found in the documents we filed with the AMF in France and the SEC in the United States, which are available in the Investor Relations section of our website.
Read the full article here